Network Pharmacology and Molecular Docking Analysis of the Mechanisms of Combined Radix Bupleuri (Chai-Hu) and Radix Paeoniae Alba (Bai-Shao) Treatment in the Prevention and Treatment of Alzheimer's Disease

被引:2
|
作者
Huang, Zhao-Han [1 ]
Fang, Yuan [2 ]
Yu, Qi [1 ]
Wang, Tong [1 ]
机构
[1] Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing, Peoples R China
[2] Shanghai Ctr Women & Childrens Hlth, Shanghai, Peoples R China
关键词
Alzheimer's disease; Bai-Shao; Chai-Hu; molecular docking; network pharmacology; POTENTIAL TARGETS; DECOCTION; INTERVENTION; QUERCETIN;
D O I
10.4103/2311-8571.372730
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Radix Bupleuri and Radix Paeoniae Alba are referred to as Chai-Hu and Bai-Shao, respectively, in Chinese. We used molecular docking and network pharmacological approaches to explore the active components of this Chinese herb combination which is commonly used for treating Alzheimer's disease (AD), the Chai-Hu and Bai-Shao pair (CBP). Materials and Methods: The active compounds and action targets of Chai-Hu and Bai-Shao were identified in the Traditional Chinese Medicine Systems Pharmacology database, and the Therapeutic Target Database, DrugBank, GenCards, DisGeNET, and Online Mendelian Inheritance in Man databases were used to identify therapeutic targets in patients with AD. To identify a common target of CBP in the treatment of AD, we used the Metascape tool to perform Gene Ontology function enrichment and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. In addition, CBP-AD protein-protein interaction (PPI) and herb-component-target networks were created using Cytoscape 3.8.2. Molecular docking was verified using AutoDock tools. Results: We identified 20 active compounds of CBP, 202 active targets, 1,323 disease targets, and 117 active compound disease intersection targets; the PPI network showed that the top eight key targets were AKT1, interleukin (IL) 6, JUN, MAPK1, tumor necrosis factor, TP53, vascular endothelial growth factor, and epidermal growth factor. These act mainly on the fluid shear stress, atherosclerosis, IL-17, hypoxia-inducible factor-1, and nonalcoholic fatty liver disease pathways, among others, which control immune inflammation, cell proliferation, and apoptosis. Based on molecular docking results, the active components of CBP bind well to its key targets. Conclusion: Our results indicated that CBP was effective for treating AD by reducing the expression of inflammatory factors, promoting cell proliferation and differentiation, and preventing nerve cell death and anti-neuronal cell apoptosis.
引用
收藏
页码:254 / 262
页数:9
相关论文
共 43 条
  • [31] Integrated systems pharmacology, molecular docking, and MD simulations investigation elucidating the therapeutic mechanisms of BHD in Alzheimer's disease treatment
    Chowdhury, Mayank Roy
    Karamveer, Karamveer
    Tiwary, Basant K.
    Nampoothiri, Navaneeth K.
    Erva, Rajeswara Reddy
    Deepa, Vijaykumar Sudarshana
    METABOLIC BRAIN DISEASE, 2024, 40 (01)
  • [32] Network pharmacology-based and molecular docking forecast mechanism of Shan Zhuyu-ShanYao for treatment in Alzheimer's disease
    Hou, Xing-yu
    Hou, Lin
    Wang, Yong-qiang
    Wang, Xiao-yu
    Jiang, Zhao-qi
    Sun, Xue
    Ding, Li-xin
    Liu, Wen-wen
    ANALYTICAL CHEMISTRY LETTERS, 2024, 14 (05) : 622 - 637
  • [33] Application of network pharmacology and molecular docking approach to explore active compounds and potential pharmacological mechanisms of Aconiti Lateralis Radix Praeparata and Lepidii Semen Descurainiae Semen for treatment of heart failure
    Yang, Meng-Qi
    Chen, Cong
    Mao, Yi-Fei
    Li, Yan
    Zhong, Xia
    Yu, Yi-Ding
    Xue, Yi-Tao
    Song, Yong-Mei
    MEDICINE, 2022, 101 (33) : E30102
  • [34] Exploring the Mechanism of Arctium Lappa L. Leaves in the Treatment of Alzheimer's Disease Based on Chemical Profile, Network Pharmacology and Molecular Docking
    Mu, Shou-chen
    Xue, Deng-feng
    Qin, Xue-mei
    Du, Guan-hua
    Zhou, Yu-zhi
    ADVANCED BIOLOGY, 2023, 7 (08):
  • [35] Molecular targets and mechanisms of Sijunzi decoction in the treatment of Parkinson's disease: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation
    Jiang, Yang
    Wu, Wanfeng
    Xie, Le
    Zhou, Yue
    Yang, Kailin
    Wu, Dahua
    Xu, Wenfeng
    Fang, Rui
    Ge, Jinwen
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [36] Integrated Network Pharmacology and Comprehensive Bioinformatics Identifying the Mechanisms and Molecular Targets of Yizhiqingxin Formula for Treatment of Comorbidity With Alzheimer's Disease and Depression
    Zhang, Tingting
    Wei, Wei
    Chang, Surui
    Liu, Nanyang
    Li, Hao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Yuan-Zhi decoction in the treatment of Alzheimer's disease: An integrated approach based on chemical profiling, network pharmacology, molecular docking and experimental evaluation
    Wu, Qiong
    Li, Xiang
    Jiang, Xiao-Wen
    Yao, Dong
    Zhou, Li-Jun
    Xu, Zi-Hua
    Wang, Nan
    Zhao, Qing-Chun
    Zhang, Zhou
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [38] Network Pharmacology-Based and Molecular Docking-Based Analysis of Suanzaoren Decoction for the Treatment of Parkinson's Disease with Sleep Disorder
    Liu, Yan-yun
    Yu, Li-hua
    Zhang, Juan
    Xie, Dao-jun
    Zhang, Xin-xiang
    Yu, Jia-ming
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [39] Exploration of the pharmacological components and therapeutic mechanisms in treatment of Alzheimer's disease with Polygonati Rhizoma and its processed product using combined analysis of metabolomics, network pharmacology, and gut microbiota
    Liao, Xiaojuan
    Liu, Hongmei
    Wang, Zhuxin
    Liu, Xiaoqin
    Deng, Lanbing
    Luo, Dan
    Zhou, Yi
    HELIYON, 2024, 10 (15)
  • [40] Integrating network pharmacology and component analysis to investigate the potential mechanisms of Sheng-Hui-Yi-Zhi decoction in the treatment of Alzheimer's disease
    Wang, Peng
    Dong, Yuan-li
    Li, Shan-shan
    Jin, Yi
    Sun, Wei-liang
    Zhao, Bao-Sheng
    Li, Qiu-bing
    Chen, Xin
    JOURNAL OF ALZHEIMERS DISEASE, 2025, 103 (03) : 666 - 678